JIUYUAN GENE (02566) has completed the filing with the China Securities Regulatory Commission regarding the full circulation of H shares.

21:16 02/04/2026

Nine Dragons Paper (02566) announced that on April 2, 2026, the China Securities Regulatory Commission issued a filing notice to the company regarding the full circulation of H shares. According to the filing notice, the company has completed the filing with the China Securities Regulatory Commission on the matter of the full circulation of H shares (related to the conversion of 136,302,015 shares of unlisted shares held by 12 company shareholders into H shares). If the share conversion is not completed within 12 months from the date of the filing notice, and the company still intends to carry out the conversion, the company shall update the filing materials with the China Securities Regulatory Commission. The company will apply to the Hong Kong Stock Exchange for the approval of the listing and trading of these H shares on the main board of the Stock Exchange.

JIUYUAN GENE (02566) announced that on April 2, 2026, the China Securities Regulatory Commission issued a filing notice to the company regarding the full circulation of H shares. According to the filing notice, the company has completed the filing with the China Securities Regulatory Commission on the matter of the full circulation of H shares (involving the conversion of 136,302,015 shares held by 12 company shareholders into H shares). If the share conversion is not completed within 12 months from the date of the filing notice, and the company still intends to proceed with the conversion, the company must update the filing materials with the China Securities Regulatory Commission. The company will apply to the Hong Kong Stock Exchange for approval for the listing and trading of these H shares on the main board of the Hong Kong Stock Exchange.

SDITC (01697) recommends appointing Zhao Zikun as an executive director of the company.

A-share evening hot topic | Major breakthrough! China's first original nuclear drug approved, is it a good opportunity to go long in the pharmaceutical sector?

CH ENERGY ENG (03996) completed the issuance of 2.549 billion A shares.

SDITC (01697) recommends appointing Zhao Zikun as an executive director of the company.

A-share evening hot topic | Major breakthrough! China's first original nuclear drug approved, is it a good opportunity to go long in the pharmaceutical sector?

CH ENERGY ENG (03996) completed the issuance of 2.549 billion A shares.